This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several ...

The company's latest venture involves the use of its proprietary Centenarian SIRT6 (cSIRT6) gene technology, which will be delivered using a non-viral vector specifically designed for targeting ...